Published August 28, 2023
| Version v1
Poster
Open
Parkinson's Progression Markers Initiative: Defining PD biology to accelerate PD therapeutics
Creators
- McMahon, Bridget1
- Siderowf, Andrew2
- Simuni, Tanya3
- Tanner, Caroline4
- Mollenhauer, Brit5
- Coffey, Christopher6
- Galasko, Douglas7
- Poston, Kathleen8
- Chahine, Lana9
- Dobkin, Roseanne10
- Foroud, Tatiana11
- Kieburtz, K.
- Weintraub, Daniel2
- Merchant, Kalpana
- Frasier, Mark12
- Sherer, Todd12
- Chowdury, Sohini12
- Brown, Ethan4
- Alcalay, Roy13
- Videnovic, A14
- Fabrizio, Kim1
- Flagg, Emily1
- Marek, Kenneth1
- 1. Institute for Neurodegenerative Disorders
- 2. University of Pennsylvania
- 3. Northwestern University
- 4. University of California, San Francisco
- 5. Paracelsus-Elena-Kliniken
- 6. University of Iowa
- 7. University of California, San Diego
- 8. Stanford University
- 9. University of Pittsburgh
- 10. Rutgers University
- 11. Indiana University
- 12. MJFF
- 13. Tel Aviv University
- 14. Massachusetts General Hospital
Description
The poster Parkinson’s Progression Markers Initiative (PPMI): Defining PD biology to accelerate PD therapeutics provides an overview of the PPMI study to date, including an update on the efforts of the expanded protocol, enrollment, and a description of the staged-risk paradigm. Most significantly it describes synuclein as a PD biomarker and proposes a biological definition of disease (Neuronal Synuclein Disease NSD) and an integrated biologic/clinical staging of NSD-ISS.
Files
Files
(3.9 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:34dee287a660b7ecd9a4a7145684ea3b
|
3.9 MB | Download |